A federal judge in Texas invalidated four key patents for the dry-eye treatment Restasis on Monday, dealing a blow to its manufacturer, Allergan, which had sought to protect its patents by transferring them to a Native American tribe

Quick Read

How to Protect a Drug Patent?

September 11, 2017

Sell it to a Native American Tribe. The drugmaker Allergan announced Friday that it had transferred its patents on a best-selling eye drug to the Saint Regis Mohawk Tribe in upstate New York — an unusual gambit to protect the drug from a patent dispute

Quick Read

Over Humira’s lifetime, AbbVie has secured more than 100 patents to prevent anyone from attempting to copy the biologic, with $16 billion in annual sales

Quick Read

Universities and other nonprofit research institutions are under increasing fire about their commitments to the public interest. In return for tax-exempt status, their work is supposed to benefit society. But are they really operating in the public interest when they wield their patent rights in ways that constrict research?

Quick Read

Marshall Allen: After I was prescribed a brand-name drug I didn’t need and given a coupon to cover the out-of-pocket costs, I discovered another reason Americans pay too much for health care.

Quick Read

If there was one misstep that doomed the long and bitter fight by the University of California to wrest key CRISPR patents from the Broad Institute, it was star UC Berkeley scientist Jennifer Doudna’s habit of being scientifically cautious, realistic, and averse to overpromising.

Quick Read

The European Patent Office announced its “intention to grant a patent” to the University of California for its broad-based claims about the genome-editing tool popularly known as CRISPR. UC, on behalf of several parties, has been in a pitched battle with the Broad Institute of Cambridge, Massachusetts, over CRISPR patents, and the new decision marks a sharp departure from the position of the USPTO

Quick Read

Last week, the US Patent and Trademarks office handed down a decision in one of the most high-profile patent cases of the century. In a one sentence ruling, an appeals board granted the rights to the powerful gene editing technology CRISPR-Cas9 to the Broad Institute of Harvard and MIT, while leaving the door open for rival CRISPR pioneer UC Berkeley to file a new patent to lay claim to those same discoveries

Quick Read